Ticker

Emmaus Life Sciences, Inc. (OTCQB: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its

TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. Highlights “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period…